John Sterling is the Editor in Chief of Genetic Engineering & Biotechnology News. With a focus on biotechnology and precision medicine, John's articles provide insights into the latest advancements and challenges in the field. His work has also been featured in publications such as Inside Precision Medicine and Upstate Business Journal.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Not enough data
John Sterling's articles primarily focus on scientific and healthcare & pharmaceutical topics, with a specific emphasis on biopharmaceutical manufacturing, bioprocessing, cell therapy, drug discovery, and biotechnology. His coverage attributes show a strong reliance on press releases and data citations.
To effectively reach out to John Sterling for potential coverage or commentary opportunities related to the mentioned themes and topics, consider offering detailed insights supported by credible data from reputable sources within the relevant industries. Additionally, providing access to newsworthy announcements or industry-specific developments may enhance the appeal of your pitch when approaching him.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: John Sterling
LCA16 is a retinal dystrophy resulting from a genetic mutation which expresses a critical ion channel in retinal pigment epithelium cells.
By: John Sterling
Both companies will focus on technology integration and marketing to ensure the successful adoption of the integrated solution.
By: John Sterling
Those famously understated words introduced a research paper written by James Watson and Francis Crick that appeared in Nature in April 1953.
By: John Sterling
The four-story buffer media station, covering 34,000 square meters, is expected to be operational by 2028 and will be integrated with the existing infrastructure, offering faster and more efficient processes, as well as ergonomically designed workstations, added von Braunmühl.
By: John Sterling
Infrastructure expansion will enable the rapid ingestion and homogenization of new multi-omics and real-world data.
By: John Sterling
Cellevate is a Swedish biotech company that develops and markets cell culture systems for cell and gene therapy and vaccine biomanufacturing. [Undefined/Getty Images]
By: John Sterling
Credit: Owngarden/Getty Images SPT Labtech and Beijing-based ICE Bioscience launched a joint laboratory focused on innovation in intelligent drug screening and life sciences automation.
By: John Sterling
Credit: MilliporeSigma MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, invested $76 million to expand its antibody
By: John Sterling
The 3D bioprinter at the Collins BioMicrosystems Laboratory at the University of Melbourne. [Tessa van der Riet]
By: John Sterling
Antibody drug conjugates can consist of a monoclonal antibody (blue/purple) and a cytotoxic payload (orange) for targeting and destroying specific cells in the body, illustration [Thom Leach/Science Photo Library/Getty Images]
(833) 317-6278 
